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Lung cancer is one of the most common deadly diseases worldwide, most of
which is non-small cell lung cancer (NSCLC). The epidermal growth factor receptor
(EGFR) mutant NSCLCs frequently respond to the EGFR tyrosine kinase inhibitors
(EGFR-TKIs) treatment, such as Gefitinib and Erlotinib, but the development of acquired
resistance limits the utility. Multiple resistance mechanisms have been explored, e.g.,
the activation of alternative tyrosine kinase receptors (TKRs) sharing similar downstream
pathways to EGFR. MicroRNAs (miRNAs) are short, endogenous and non-coding
RNA molecules, regulating the target gene expression. In this study, we explored the
potential of miR-30a-5p in targeting the EGFR and insulin-like growth factor receptor-1
(IGF-1R) signaling pathways to overcome the drug resistance. IGF-1R is one of the
tyrosine kinase receptors that share the same EGFR downstream molecules, including
phosphatidylinositol 3 kinase (PI3K) and protein kinase B (AKT). In this work, an in vitro
study was designed using EGFR inhibitor (Gefitinib), IGF-1R inhibitor (NVP-AEW541),
and miRNA mimics in two Gefitinib-resistant NSCLC cell lines, H460 and H1975. We
found that the combination of EGFR and IGF-1R inhibitors significantly decreased the
phosphorylated AKT (p-AKT) expression levels compared to the control group in these
two cell lines. Knockdown of phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2)
had the same effect with the dual inhibition of EGFR and IGF-1R to reduce the expression
of p-AKT in the signaling pathway. Overexpression of miR-30a-5p significantly reduced
the expression of the PI3K regulatory subunit (PIK3R2) to further induce cell apoptosis,
and inhibit cell invasion and migration properties. Hence, miR-30a-5p may play vital roles
in overcoming the acquired resistance to EGFR-TKIs, and provide useful information for
establishing novel cancer treatment.
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INTRODUCTION
Lung cancer, particularly non-small cell lung cancer (NSCLC), is
one of the top cancers leading to death worldwide. Every year
there are more than 4000 new cases and the 5-year survival rate
is around 15% only (Ho, 2011). The early detection is applied
to clinical screening on a large scale and most of patients are
diagnosed with NSCLCs (Breuer et al., 2005). However, the
survival rate is still very low. In order to improve the survival,
much attention has been paid to explore the new therapeutic
approaches focusing on the molecular mechanisms that regulate
tumor cell growth, such as the target therapy on epidermal
growth factor receptor (EGFR; Camp et al., 2005). EGFR tyrosine
kinase inhibitors (TKIs) are small molecules that bind to the
tyrosine kinase domain of EGFR to inhibit its phosphorylation
and the subsequent receptor activation and signal transduction
(Camp et al., 2005). However, tumors usually progress due to the
acquired resistance to EGFR-TKIs (Yu et al., 2013). No curative
therapy is available for NSCLC patients with such resistance, even
though the irreversible EGFR-TKIs and other novel agents are
under development (Zhang et al., 2012; Yu et al., 2013). Multiple
molecular mechanisms of resistance have been explored, such
as the activation of alternative tyrosine kinase receptors (TKRs)
that bypass the EGFR signaling pathway, and the secondary
mutations in EGFR T790M (Camp et al., 2005; Zhang et al.,
2012).
Researchers found that other TKRs are activated, including
hepatocyte growth factor receptor (c-MET) and insulin-
like growth factor receptor-1 (IGF-1R), which share similar
downstream pathways with EGFR (Camp et al., 2005). The
activation of these alternative TKRs could mimic the function
of EGFR by regulating the overlapping signal transduction
pathways to stimulate the survival mechanisms (Camp et al.,
2005). IGF-1R is an important tyrosine kinase that is involved
in malignant transformation and acquired resistance of many
human cancers (Guevara-Aguirre et al., 2011; Chan et al., 2015).
It has been reported that the activation of IGF-1R is related
to EGFR-TKIs resistance in NSCLC cell lines and lung cancer
patients (Peled et al., 2013; Yeo et al., 2015). Researchers also
found that IGF-1R tyrosine kinase inhibitors can reverse the
resistance of EGFR-TKIs in vitro and in vivo (Morgillo et al.,
2006; Zhou et al., 2015). Evidences suggest a role of IGF-1R in
the progression of tumor and a functional cross talk between
EGFR and IGF-1R (Tandon et al., 2011). Double inhibiting
EGFR and IGF-1R may be a potential strategy to reverse
the drug resistance against the 2nd or 3rd generation EGFR
inhibitors (Chan et al., 2015). However, the exact mechanisms
of IGF-1R-induced acquired drug resistance in NSCLC remain
unclear.
MicroRNAs (miRNAs) are short, endogenous and non-coding
RNA fragments of 21–25 nucleotides, which can inhibit mRNA
translation or promote mRNA degradation (Yeo et al., 2015).
MiRNAs are very important in human tumors for altering the
expression of target oncogenes or tumor suppressor genes (Zhou
et al., 2015). The dysregulation of miRNA contributes much
to cancer development and cancer drug resistance (Morgillo
et al., 2006; Yeo et al., 2015). Researchers reported that miR-30b,
miR-30c, miR-221, and miR-222 affect the Gefitinib-induced
apoptosis and epithelial-mesenchymal transition of NSCLC
cells by inhibiting some important oncogenes expression, e.g.,
sarcoma viral oncogene homolog (SRC; Yeo et al., 2015).
Furthermore, miR-494 can alter the drug resistance by regulating
the expression of Bcl-2-like protein 11 (BIM; Tandon et al.,
2011). The regulatory effects of miRNAs on EGFR signaling
pathway in NSCLCs have been widely studied. MiR-128b directly
regulates the expression of EGFR, whose loss-of-heterozygosity
is frequently found in NSCLCs and promotes the clinical
response and survival rate after Gefitinib treatment (Davalos
et al., 2012). Moreover, miR-7 regulates various genes in the
EGFR signaling pathway, including EGFR, Raf1, AKT, and
ERK, indicating that miR-7 could inhibit the EGFR signaling
pathway (Pao et al., 2005). As such, miRNAs are important
to affect the resistance to EGFR-TRIs in the EGFR signaling
pathway.
IGF-1R can activate the EGFR shared downstream
signaling pathways, one of which is the phosphatidylinositol
3 kinase/protein kinase B (PI3K/AKT) pathway (Zhou et al.,
2015). In this study, we selected two key markers in the shared
downstream signaling pathways PI3K and AKT to verify the
effect of a candidatemiRNAmiR-30a-5p on the drug resistance in
NSCLCs. MiR-30a-5p is predicted to regulate phosphoinositide-
3-kinase regulatory subunit 2 (PIK3R2) by TargetScan (Agarwal
et al., 2015) and PicTar (Krek et al., 2005) prediction databases.
Furthermore, our previous study revealed that miR-30a-5p was
negatively associated with the expression of PIK3R2 based on
the multiple linear regression and support vector regression
models (Wang et al., 2016). We hypothesize that inhibition of
the shared downstream molecules (e.g., PI3K) of EGFR and
IGF-1R can overcome the resistance of EGFR-TKIs. MiRNAs
regulating the shared downstream molecules have the same
effect to reverse the drug resistance. To prove our hypothesis,
an in vitro study was performed using EGFR inhibitor, IGF-1R
inhibitor, and miRNA mimics in two Gefitinib-resistant NSCLC
cell lines, NCI-H1975 with a secondary T790M mutation in
EGFR, and NCI-H460. This study could identify miRNA roles in
overcoming the acquired resistance to EGFR-TKIs, and explore
new mechanisms of NSCLCs.
MATERIALS AND METHODS
Cell Culture and Reagents
The cell lines NCI-H460 and NCI-H1975 were purchased
from the Type Culture Collection of the Chinese Academy of
Sciences (Shanghai, China). Cells were grown in RPMI-1640
supplemented with 10% fetal bovine serum (FBS), and incubated
at 37◦C, 5% CO2. The EGFR inhibitor Gefitinib (#4765) was
purchased fromCell Signaling Technology. The IGF-1R inhibitor
NVP-AEW541 (#S1034) was purchased from Selleckchem. RIPA
lysis and extraction buffer (#89900) used to lyse cells was
purchased from ThermoFisher. PIK3R2-shRNA (#sc-39125-
SH) and the Control shRNA Plasmid-A (#sc-108060) were
purchased from Santa Cruz Biotechnology. MiR-30a-5p mimics
(5′-UGUAAACAUCCUCGACUGGAAG-3′) and the negative
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control RNA oligo (5′-UUCUCCGAACGUGUCACGUTT-
3′) were purchased from GenePharma. PIK3R2-shRNA
and miR-30a-5p mimics were transfected by lipofectamine
2000 reagent (#12566014) purchased from ThermoFisher.
Annexin V-FITC Apoptosis Detection Kit (#K101-25) was
purchased from BioVision. The CytoSelectTM Cell Invasion
Assay Kit (#CBA-110) was purchased from CELL BIOLABS,
INC.
Western-Blotting and Antibodies
Protein fractions were extracted from cells. Cells were washed
twice in Phosphate-buffered saline (PBS). We then scraped the
cells from plates using tips. Samples were homogenized in ice
by the addition of 400 µl RIPA lysis buffer containing 1 mM
sodium ortho vanadate and protease inhibitors cocktail, and then
maintained constant agitation for 30 min at 4◦C. The lysates
were collected by centrifugation at 13000 rpm for 20 min at
4◦C. Protein concentration was measured by Bradford assay
(Coomassie Protein Assay, Pierce, Rockford, IL, USA), and the
bovine serum albumin (BSA) was used as the standard. Thirty
micrograms/lane of protein was loaded on 8% polyacrylamide gel
and subjected to electrophoretic separation by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS–PAGE). After
that, proteins were transferred to polyvinylidene difluoride
(PVDF) membranes (Immobilon P, Millipore, Billerica, MA,
USA) and probed with specific primary antibodies from Cell
Signaling Technology, USA (EGF Receptor (D38B1) XP R©
Rabbit mAb, #4267, 1:1000; Phospho-EGF Receptor (Tyr1068)
(D7A5) XP R© Rabbit mAb, #3777, 1:1000; IGF-I Receptor β
(D23H3) XP R© Rabbit mAb, #9750, 1:1000; Phospho-IGF-I
Receptor β (Tyr1135/1136)/Insulin Receptor β (Tyr1150/1151)
(19H7) Rabbit mAb, #3024, 1:1000; PI3 Kinase p85 Antibody,
#4292, 1:1000; AKT (pan) (C67E7) Rabbit mAb, #4691, 1:1000;
Phospho-AKT (Ser473) (D9E) XP R© Rabbit mAb, #4060, 1:2000;
GAPDH (D16H11) XP R© Rabbit mAb, #5174, 1:2000), and then
incubated with the appropriate horseradish peroxidase (HRP)-
conjugated secondary antibodies (Anti-rabbit IgG, HRP-linked
Antibody, #7074, 1:3000). The chemiluminescent was detected
by a Kodak 4000R Pro camera. The resulting bands from western
blotting were quantified as optical density (OD)× band area and
expressed as arbitrary units. GAPDHwas probed as the reference
of internal control. All the data were normalized to the signal of
GAPDH.
Dual Inhibition of EGFR and IGF-1R
Gefitinib and AEW541 were used in combination to test the
inhibition effect on the signaling pathway. The concentrations
of Gefitinib and AEW541 were formulated according to the
manufacturer’s instructions. The 10mM stock of Gefinitib
reconstituted the 10mg power in 2.24ml DMSO. The 10mg
AEW541 power was dissolved in 2.2751ml DMSO to form
10mM stock. The appropriate stocks were took to dilute to 2
µM concentrations in culture medium containing 10% FBS.
Cells were seeded in 6-well plates with 70–80% confluency in
each well after 24 h incubation, and aspirated the old medium.
Cells were then respectively treated with 2 ml prepared medium
with Gefitinib, AEW541, and the combination of Gefitinib and
AEW541 for 6 h. The expression levels of phosphorylated
and total signaling proteins were detected by western
blotting.
Knockdown of PI3K through
PIK3R2-shRNA Transfection
The PI3K regulatory subunit PIK3R2 was chosen for the
knockdown analysis. PIK3R2 knockdown assays were carried
out using lipofectamine 2000 kit to transfect PIK3R2-shRNA
into cells. Cells were seeded in 6-well plates with 70–80%
confluency in each well for 24 h incubation. PIK3R2-shRNA
(2.5 µg) in 125 µl of Opti-MEM R© I Reduced Serum Medium
(#31985062, ThermoFisher) mixed with 5 µl of lipofectamine
2000 transfection reagent dissolved in 125 µl of the same
medium and allowed to stand at room temperature for 20
min according to the manufacturer’s instructions. After that,
the resulting 250 µl transfection solutions were added to
each well with 1.75ml of medium. The cultures were then
replaced with 2ml fresh medium supplemented with 10% FBS
after 6 h. The Control shRNA Plasmid-A in the lipofectamine
2000 was added as the negative control group, and only
lipofectamine 2000 reagent as the blank control group. After
24 h incubation, cells were lysed to extract proteins and




Cells were seeded in glass-bottom dishes and 6-well plates
with 70–80% confluency in each well after 24 h incubation.
MiR-30a-5p mimics (75 pmol) in 125 µl of Opti-MEM R© I
Reduced Serum Medium mixed with 5 µl of lipofectamine
2000 transfection reagent dissolved in 125 µl of the same
medium and allowed to stand at room temperature for 20
min according to the manufacturer’s instructions. After that,
the resulting 250 µl transfection solutions were added to each
well with 1.75 ml of medium. The cultures were then replaced
with 2ml fresh medium supplemented with 10% FBS after
6 h. After that, the cells were incubated for 24 h. The RNA
oligo in the lipofectamine 2000 was added as the negative
control group, and only lipofectamine 2000 reagent as the
blank control group. The resulted samples were used for the
western blotting, cell apoptosis, invasion, and wound healing
assays.
Cell Apoptosis Assay
The cell apoptosis assay was performed using the Annexin V-
FITC Apoptosis Detection Kit according to the manufacturer’s
instructions. The cells in glass-bottom dishes from the resulted
sample were washed twice in PBS, and added 500 µl 1 X
binding buffer. And then added 5 µl of Annexin V-FITC
and 5 µl of propidium iodide, and incubated for 5 min in
the dark at room temperature. The microscope was used to
detect the signals and take images. Cells bound to Annexin
V-FITC show green staining in the plasma membrane, while,
cells lost membrane integrity show red staining throughout the
nucleus and green staining on the cell surface. The microscope
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was used to detect the apoptosis signals and take images at
6 and 12 h after adding Annexin V-FITC. We counted the
number of apoptotic and total cells under 40X objective in
three individual fields per dish for each biological repeat.
The cell apoptosis rate was calculated based on the equation:
percentage apoptosis rate = apoptotic cell number/total cell
number∗100.
Cell Invasion Assay
We performed the cell invasion assay using CytoSelectTM Cell
Invasion Assay Kit according to the manufacturer’s instructions.
Five-hundred microliters of medium containing 10% FBS was
added to the lower well of the invasion plate. Three-hundred
microliters of cell suspension solution from the resulted samples
with the concentration of 1.0 × 106 cells/ml in serum free
medium was then added to the upper chamber of the kit. The
cells were incubated for 24 h at 37◦C, 5% CO2. During this
process, the invasive cells went through the basement membrane
layer of the kit and attached to the bottom of the insert
membrane, while the non-invasive cells stayed in the upper
chamber. The non-invasive cells were removed carefully. The
invasive cells were transferred to a clean well containing 400
µl of Cell Stain Solution and incubated for 10 min at room
temperature. The microscope was used to image the invasive
cells. Gently washed the stained cells in 200 µl Extraction
Solution and incubated for 10 min. One-hundred microliters
of the resulted solution was then transferred to a 96-well
microtiter plate and measured the OD 560 nm in a microplate
reader.
Wound Healing Assay
The wound healing assay was used to indicate the cell migration
ability. A straight scratch wasmade gently through themonolayer
cells using an Eppendorf tip in 6-well plates from the resulted
samples. Detached cells were washed away using PBS buffer
and the serum-free culture medium was added. Cell migrating
FIGURE 1 | Effect of EGFR inhibitor (Gefitinib), IGF-1R inhibitor (AEW541), and the combination (Gefitinib+AEW541) on the protein expression levels of
total and phosphorylated EGFR, IGF-1R and AKT. (A) Protein expression in H460 cell line. (B) Protein expression in H1975 cell line. GAPDH was used as an
internal control. The chart results were presented as the mean of three independent experiments. Blots were the representative of three independent experiments.
*P < 0.05, one-way ANOVA used to compare four groups.
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to the scratch was monitored and took images at 0, 12, and
24 h after given the wound using microscope. The migration
rate was calculated according to the equation: percentage
wound healing = ((wound length at 0 h) − (wound length
at 12 or 24 h))/(wound length at 0 h)∗ 100 (Davalos et al.,
2012).
Statistical Analysis
The statistical analyses were performed by IBM SPSS Statistics
24.0 software. Three independent experiments were performed
for western blotting, cell apoptosis, invasion and wound healing
assays. All the experimental values were given as the mean ±
standard error of the mean (SEM). One-way ANOVA followed
by Tukey’s post-hoc test was performed to make the comparisons
for western blotting. The Student t-test was applied to determine
the statistical significance in the cell apoptosis, invasion, and
wound healing assays. Significant differences were considered at
p < 0.05.
RESULTS
Combination of EGFR and IGF-1R
Inhibitors Blocks the PI3K/AKT Signaling
Pathway
H460 and H1975 cells were treated with Gefitinib, AEW541,
and the combination of Gefitinib and AEW541, respectively. In
order to explore the effects at the mechanistic level, we tested
the phosphorylation levels of related proteins after treatment.
One-way ANOVA revealed that there were significant differences
among the four groups (including three experiment and one
control groups) with p < 0.05 for the expression levels of
p-EGFR, p-IGF-1R, and p-AKT in both H460 and H1975 cells
(Figure 1). Interestingly, we identified that IGF-1R inhibitor
(AEW541) could affect the expression of p-EGFR in both H460
and H1975 cells. Notably, we found that the combination
of Gefitinib and AEW541 inhibitors significantly decreased
p-IGF-1R and p-AKT expression levels compared to the only
FIGURE 2 | Effect of PIK3R2-shRNA knockdown on the protein expression levels of PIK3R2 and AKT. (A) Protein expression in H460 cell line. (B) Protein
expression in H1975 cell line. GAPDH was used as an internal control. The chart results were presented as the mean of three independent experiments. Blots were
the representative of three independent experiments. *P < 0.05, one-way ANOVA used to compare three groups.
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Gefitinib, only AEW541 and control groups from Tukey’s post-
hoc test in both of the two cell lines (p < 0.05). AKT is
the downstream molecule in the signaling pathways, and the
expression level of its phosphorylated form was the least in the
dual inhibitors group compared to the other three groups. Hence,
the combination of EGFR and IGF-1R inhibitors treatment could
block the PI3K/AKT signaling pathway.
Treatment with PI3K-shRNA Decreases the
Expression Level of p-AKT
PIK3R2-shRNA was transfected into H460 and H1975 cells.
The results demonstrated that the PIK3R2 expression level was
significantly decreased after the transfection compared to the
negative and blank control groups from Tukey’s post-hoc test
(p < 0.05; Figure 2). The expression level of its phosphorylated
downstream molecule p-AKT was also significantly decreased in
the shRNA knockdown group compared to the control groups
(p < 0.05). PI3K is the shared downstream molecule of EGFR
and IGF-1R. Inhibition of PI3K regulatory subunit PIK3R2 could
decrease the expression level of p-AKT and block the subsequent
signaling pathway in both H460 and H1975 cells.
Treatment with miR-30a-5p Mimics
Decreases the Expression Levels of
PIK3R2 and p-AKT and Induces Cell
Apoptosis
MiR-30a-5p mimics were further transfected to H460 and H1975
cells. Treatment with miR-30a-5p mimics significantly decreased
the expression level of PIK3R2 and p-AKT compared to the
negative and blank control groups from Tukey’s post-hoc test
(p < 0.05; Figure 3). The cell apoptosis assay was further
performed to demonstrate the effect of miR-30a-5p mimics on
the apoptosis in both H460 and H1975 cells. The microscope
was used to detect the apoptosis signals and take images at 6
and 12 h after adding Annexin V-FITC. The cell apoptosis rate
was then calculated accordingly. Our results revealed that the
FIGURE 3 | Effect of miR-30a-5p mimics on the protein expression levels of EGFR, PIK3R2, and AKT. (A) Protein expression in H460 cell line. (B) Protein
expression in H1975 cell line. GAPDH was used as an internal control. The chart results were presented as the mean of three independent experiments. Blots were
the representative of three independent experiments. *P < 0.05, one-way ANOVA used to compare three groups.
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cell apoptosis rate was significantly increased at both 6 and 12
h after miR-30a-5p mimics transfection when compared to the
negative control group in both H460 and H1975 cells (p < 0.05;
Figure 4).
Treatment with miR-30a-5p Mimics Inhibits
Cell Invasion and Migration
We also tested the invasion and migration properties after
the transfection of miR-30a-5p mimics. The microscope was
used to take images for cell invasion. The invasion ability
was evaluated based on the OD 560 nm value. The results
demonstrated that the invasive cells were significantly decreased
in the miR-30a-5p mimics transfected group compared to the
negative control group in both H460 and H1975 cells (Figure 5).
Cell migration was detected and imaged using microscope
at 0, 12, and 24 h after the wound to investigate the role
of miR-30a-5p in cell migration. Notably, the cell migration
rate was significantly decreased at both 12 and 24 h when
treated with miR-30a-5p mimics compared to the negative
control group in both H460 and H1975 cells (p < 0.05;
Figure 6).
DISCUSSION
In this study, we explored the miR-30a-5p roles in overcoming
the drug resistance in the EGFR and IGF-1R signaling pathways
in two Gefitinib-resistant NSCLC cell lines, NCI-H460 and NCI-
H1975. IGF-1R is one of the tyrosine kinase receptors that share
the same downstream molecules with EGFR. Researchers have
found that IGF-1R can activate the shared PI3K/AKT signaling
pathway (Zhou et al., 2015). Dual inhibition of EGFR and IGF-
1R was done to reverse the drug resistance and test PI3K/AKT
signaling pathway. We further inhibited the expression
of PI3K through shRNA to investigate its phosphorylated
downstream molecule p-AKT expression level. MiR-30a-5p
mimics were transfected into cells to verify its role in cancer cell
FIGURE 4 | Cell apoptosis assay after miR-30a-5p mimics transfected at 6 and 12h. (A) Cell apoptosis assay in H460 cell line. (B) Cell apoptosis assay in
H1975 cell line. The chart results were presented as the mean of three independent experiments. Representative microscope images were given. Green color
indicates the early stage of cell apoptosis, and the red color represents the apoptotic cells at the late stage.
Frontiers in Genetics | www.frontiersin.org 7 November 2016 | Volume 7 | Article 197
Meng et al. MiR-30a-5p Overcomes NSCLC’s EGFR-TKI Resistance
FIGURE 5 | Cell invasion assay after miR-30a-5p mimics transfected in H460 and H1975 cell lines. Invasive cells on the bottom of the invasion membrane
were stained and quantified at OD 560 nm after extraction. The chart results were presented as the mean of three independent experiments. *P < 0.05, t-test used to
compare two groups.
apoptosis, invasion and migration properties and the signaling
pathway.
Dual inhibition of EGFR and IGF-1R could block the
PI3K/AKT signaling pathway. We found that EGFR inhibitor
by its own could not reduce the expression level of p-AKT,
but the combination of EGFR inhibitor and IGF-1R inhibitor
significantly lowered the p-AKT levels compared to the control
group (Figure 1). The PI3K/AKT pathway is one of the major
signaling networks that transduce the activated EGFR signals,
leading to cell proliferation, and survival (Sharma et al., 2007;
Gandhi et al., 2009). We found that treatment with PIK3R2-
shRNA significantly decreased the expression level of p-AKT
(Figure 2). Knockdown of PI3K had the same effect with the dual
inhibition of EGFR and IGF-1R to reduce the expression of the
phosphorylated downstream molecule p-AKT in the signaling
pathway, indicating that PI3K could be regarded as a potential
drug target for TKI-resistant NSCLC treatment. PI3K is a kind
of enzyme that phosphorylates phosphatidylinositol biphosphate
to phosphatidylinositol triphosphate, which is highly activated
by receptor tyrosine kinase signaling molecules, including
EGFR and IGF-1R (Kurosu et al., 1997; Roche et al., 1998;
Vanhaesebroeck and Waterfield, 1999; Cantley, 2002; Zito et al.,
2012). Phosphatidylinositol triphosphate can activate AKT to
mediate protein synthesis, cell growth and survival (Engelman
et al., 2006; Zito et al., 2012). It has been found that PI3K
might be a valuable drug target (Zito et al., 2012). Dual
inhibition of PI3K and mTOR was synergistic in the NSCLC
cell lines in vitro and further leaded to cell growth inhibition
and apoptosis (Zito et al., 2012). Combining PI3K and mTOR
inhibitors has been verified the promising activity in various
malignancies (Serra et al., 2008; Brachmann et al., 2009; Aziz
et al., 2010).
The dysregulation of miRNAs makes a great contribution
to cancer development and cancer drug resistance (Morgillo
et al., 2006; Yeo et al., 2015). It has been reported that
miR-30b, miR-30c, miR-221, and miR-222 affect the Gefitinib-
induced apoptosis and epithelial-mesenchymal transition of
NSCLC cells by inhibiting the expression of some important
oncogenes (Yeo et al., 2015). MiR-30a-5p is predicted to
regulate PIK3R2 by TargetScan and PicTar, which was also
found to be negatively associated with the expression of
PIK3R2 from microarray data analysis (Wang et al., 2016).
We identified that treatment with miR-30a-5p mimics could
significantly inhibit PIK3R2 expression to further reduce the
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FIGURE 6 | Cell wound healing assay after miR-30a-5p mimics transfection. Cell migrating to the scratch was monitored and took images at 0, 12, and 24 h
after given the wound using microscope. (A) Cell wound healing assay in H460 cell line. (B) Cell wound healing assay in H1975 cell line. The chart results were
presented as the mean of three independent experiments. Representative microscope images of wound healing were given. The wound length was used to calculate
the migration rate.
level of p-AKT in cell lines (Figure 3). We also investigated
the role of miR-30a-5p in cell properties. Overexpression of
miR-30a-5p could induce cell apoptosis, as well as inhibit
cell invasion and migration (Figures 4–6). MiRNAs are
remarkable for drug discovery in cancer treatment. Researchers
have tested a liposomal nanoparticle loaded with synthetic
miRNA-34a mimics (MRX34) against cancer cells combined
with the EGFR-TKI Erlotinib (Bader, 2012; Zhao et al.,
2014).
In this study, we identified that dual inhibition of EGFR
and IGF-1R could block the PI3K/AKT signaling pathway.
NSCLC cell line H1975 has the T790M EGFR mutation and
is resistant to EGFR-TKIs, such as Gefitinib and Erlotinib
(Pao et al., 2005; Tandon et al., 2011). The activation of
IGR-1R signaling pathway may be a novel mechanism that
leading to drug resistance in H1975, except for EGFR mutation.
The same findings were also identified in another Gefitinib-
resistant NSCLC cell line, H460. Knockdown of the shared
downstream molecule PI3K could decrease the expression
level of p-AKT, indicating PI3K may be a potential drug
target for cancer treatment. Overexpression of miR-30a-5p
could significantly reduce the PI3K regulatory subunit PIK3R2
expression to further induce cell apoptosis, inhibit cell invasion
and migration properties. Hence, combination of miR-30a-5p
and other EGFR-TKIs may increase the cancer cell sensitivity
to targeted drugs and provide a novel approach for NSCLC
treatment.
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